Tesamorelin
A GHRH analogue with something rare in this catalogue: an approved clinical indication and the trial data behind it.
A GHRH analogue studied in clinical trials for reducing visceral fat, by raising the body’s own growth hormone release.
- Also known as
- TH9507; Egrifta
- Class
- Growth hormone-releasing hormone (GHRH) analogue
- Evidence
- Approved medicine
- FDA
- Approved (2010) for excess abdominal fat in people with HIV
- WADA 2026
- Prohibited at all times under S2 (named)
Concentrations · 1 vial
from R 5005mg selected — in stock and shipping now.
About Tesamorelin
Tesamorelin is a growth hormone releasing hormone analogue, and it is one of the few compounds here that went through the full clinical development path. It is approved in the United States for reducing excess visceral abdominal fat in a specific patient population, which means its effect on visceral fat is not inferred from mechanism — it was the trial endpoint.
Visceral fat is what makes it interesting beyond that population. It is the fat around the organs rather than under the skin, it responds differently to diet than subcutaneous fat does, and it is the fraction most closely tied to metabolic risk. A compound with trial data specifically on that fraction is unusual. The research also covers cognitive endpoints, which follows from what raising growth hormone does more broadly.
Specifications
Evidence level: Approved medicine · FDA-approved in 2010 as Egrifta, for excess abdominal fat in HIV-associated lipodystrophy.
- Formula
- C221H366N72O67S PubChem ↗
- Molecular weight
- 5136 g/mol
- CAS number
- 218949-48-5
What it’s researched for
Research context, not medical advice. Everything we sell is supplied for research purposes.
Visceral fat
The clinical endpoint the compound was approved on — the deep abdominal fat around the organs, not the subcutaneous layer.
Body composition
Studied for the broader composition picture that follows from sustained GH elevation rather than for scale weight.
Cognitive function
A secondary research interest, consistent with the wider literature on growth hormone and cognition.
What the research does not show
The limits of the evidence, stated as plainly as the findings.
- Proven benefits outside the HIV population it is approved for.
- That a research vial is the same as the registered medicine. It is a different, unregistered product.
Reconstitution and storage
The 10mg vial with 2 mL of bacteriostatic water gives 5mg/mL. Unopened vials are stable at room temperature in transit but belong in a fridge once they arrive, and out of a parked car in a Highveld summer.
Questions we get about Tesamorelin
Sources
- Falutz J, Allas S, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 2007.
- Falutz J, Mamputu JC, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology and Metabolism, 2010.
- Stanley TL, Feldpausch MN, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 2014.
- World Anti-Doping Agency. International Standard Prohibited List 2026. WADA, 2025.
Order Tesamorelin in South Africa
Everything ships from Johannesburg, nationwide. Add it to your order slip, send the slip on WhatsApp, and we’ll confirm stock, pricing and delivery before you pay a cent.